ORYZON GENOMICS SA
Oryzon Genomics is a biopharmaceutical company developing epigenetics-based therapeutics for patients with cancer and CNS disorders. Oryzon is able to identify and validate biomarkers and therapeutic targets through its epigenetic platform and turn them into advanced and personalized therapies. Oryzon Genomics has a growing portfolio, with two compounds in Phase II clinical trials: iadademstat (aka ORY-1001), a potent and selective LSD1 inhibitor for oncology, and vafidemstat (aka ORY-2001), a CNS optimized LSD1 inhibitor for the treatment of neurological diseases. The portfolio includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases.
ORYZON GENOMICS SA
Social Links:
Industry:
Biopharma Biotechnology Genetics Health Care Medical Therapeutics
Founded:
2000-06-02
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Website Url:
http://www.oryzon.com
Total Employee:
11+
Status:
Active
Contact:
34 93 515 13 13
Email Addresses:
[email protected]
Total Funding:
162.38 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Domain Not Resolving
Similar Organizations
CureVac
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.
Elasmogen
Elasmogen is a precision biologics drug discovery company that develops soloMERs.
Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
immatics biotechnologies
immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Medicinal Genomics
Medicinal Genomics is pioneering the genomics of medical cannabis and hemp.
Medreich
Medreich is a fully integrated pharmaceutical company with an established presence across the globe.
NuCana BioMed
NuCana BioMed, a biopharmaceutical company, develops and commercializes rationally designed medicines for significant unmet medical needs.
Oxford BioMedica
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research.
Pepgen
PepGen is empowering nucleic acid therapeutics to go the distance.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Regulus Therapeutics
Regulus Therapeutics is a clinical stage biopharmaceutical company focused on the development and discovery of microRNA therapeutics.
Theolytics
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.
Theranexus
Theranexus is a clinical-stage pharmaceutical company that aims to develop technology to address severe medical needs in brain disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2009-03-20 | Crystax Pharmaceuticals | Crystax Pharmaceuticals acquired by Oryzon Genomics SA | N/A |
Investors List
Nice & Green SA
Nice & Green SA investment in Convertible Note - Oryzon Genomics SA
European Commission
European Commission investment in Grant - Oryzon Genomics SA
Kabuki Syndrome Foundation
Kabuki Syndrome Foundation investment in Grant - Oryzon Genomics SA
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Grant - Oryzon Genomics SA
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Grant - Oryzon Genomics SA
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Grant - Oryzon Genomics SA
ICF Capital
ICF Capital investment in Venture Round - Oryzon Genomics SA
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Grant - Oryzon Genomics SA
Laboratorios Ordesa
Laboratorios Ordesa investment in Series B - Oryzon Genomics SA
Corsabe Capital
Corsabe Capital investment in Series B - Oryzon Genomics SA
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-28 | ORYZON Announces Appointment of Douglas V. Faller, MD, PhD as Global Chief Medical Officer and Continues its Expansion of US Corporate Activities |
Official Site Inspections
http://www.oryzon.com Semrush global rank: 1.67 M Semrush visits lastest month: 14.63 K
- Host name: 104.26.8.59
- IP address: 104.26.8.59
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Oryzon Genomics SA"
Oryzon Genomics SA - Crunchbase Company Profile
Oryzon Genomics is a biopharmaceutical company developing epigenetics-based therapeutics for patients with cancer and CNS disorders.See details»
Oryzon Genomics (BME:ORY) Company Profile & Description
Mar 14, 2025 Company profile for Oryzon Genomics S.A. (BME:ORY) with a description, list of executives, contact details and other key facts.See details»
Oryzon Genomics 2025 Company Profile: Stock Performance
Information on stock, financials, earnings, subsidiaries, investors, and executives for Oryzon Genomics. Use the PitchBook Platform to explore the full profile.See details»
Oryzon Genomics - Biotech Spain
Mar 31, 2025 Oryzon’s management team is composed of passionate biopharma executives exploring new fields of epigenetic science to transform it into innovative personalized …See details»
Oryzon - Overview, News & Similar companies | ZoomInfo.com
View Oryzon (www.oryzon.com) location in Catalonia, Spain , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Oryzon - Overview, News & Competitors | ZoomInfo.com
Oryzon is the leader in the development of therapeutics in the epigenetic target LSD1: Oryzon has a program in oncology, iadademstat (ORY-1001), in Phase IIa in leukemia and in small cell …See details»
Overview | Oryzon
Overview ORYZON is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on …See details»
ORYZON Reports Financial Results and Corporate Update for
Feb 28, 2025 Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical …See details»
Presentación de PowerPoint - Swiss Biotech Day
Pioneering personalized medicine in epigenetics ORYZON is a clinical stage biopharmaceutical company and a leader in the development of epigenetics-based therapeutics. We are …See details»
ORYZF | Oryzon Genomics S.A. Company Profile & Executives - WSJ
Company profile for Oryzon Genomics S.A. including key executives, insider trading, ownership, revenue and average growth rates. View detailed ORYZF description & address.See details»
Ozmosi | ORY-4001 Drug Profile
In 2022, Oryzon and the CMT Research Foundation (CMTRF), a U.S.-based patient-led, non-profit organization focused on delivering treatments and cures for CMT, entered into an …See details»
ORYZON to Reshape Its Board of Directors at the Upcoming …
Jan 27, 2025 Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 …See details»
Expanding Analyst Interest in ORYZON - Morningstar
13 hours ago Oryzon is further expanding the clinical development of iadademstat through additional investigator-initiated studies in oncology, and it has announced plans to expand its …See details»
Expanding analyst interest in ORYZON | Oryzon
13 hours ago About Oryzon Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in …See details»
ORYZON Reports Results and Corporate Update for Quarter
May 5, 2022 Oryzon Genomics, S.A. reported financial results for the first quarter of 2022 and provided an update on recent developments.See details»
Oryzon Genomics SA (Oryzon Genomics SA) - 药物管线_专利_临床 …
Jun 26, 2025 Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical …See details»
Press releases | Oryzon
Apr 21, 2025 ORYZON awarded 13.26 million € through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)See details»
ORYZON to Provide Corporate Progress Updates at Several Events …
May 27, 2025 Oryzon has been invited to present at the Discovery and Development Europe 2025 conference, organized by Oxford Global, which will be held at the Congress Center in …See details»
ORYZON reports financial results and corporate update for Q4 2024
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical …See details»
ORYZON Reports Financial Results and Corporate Update for
Feb 27, 2025 Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego.See details»